ADReCS

Pharmaceutical Information

Drug Name	Azathioprine
Drug ID	BADD_D00195
Description	Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage	Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status	approved
ATC Code	L04AX01
DrugBank ID	DB00993
KEGG ID	D00238
MeSH ID	D001379
PubChem ID	2265
TTD Drug ID	D07QCE
NDC Product Code	62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII	MRK240IY2L
Synonyms	Azathioprine \| Azothioprine \| Imurel \| Imuran \| Immuran \| Azathioprine Sodium \| Sodium, Azathioprine \| Azathioprine Sodium Salt \| Azathioprine Sulfate

Chemical Information

Molecular Formula	C9H7N7O2S
CAS Registry Number	446-86-6
SMILES	CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Colon cancer	16.13.01.001; 07.21.01.001	0.000470%		Not Available
Condition aggravated	08.01.03.004	0.010559%		Not Available
Conjunctivitis allergic	06.04.01.003; 10.01.04.002	0.000313%		Not Available
Constipation	07.02.02.001	-	-
Conversion disorder	19.24.01.001	0.000313%		Not Available
Cough	22.02.03.001	-	-
Crohn's disease	10.02.01.005; 07.08.01.015	0.033618%		Not Available
Crying	19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.005	0.000470%		Not Available
Cushing's syndrome	24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.001	0.000313%		Not Available
Cutaneous vasculitis	24.12.04.008; 23.06.02.001; 10.02.02.003	0.000627%		Not Available
Cyst	08.03.05.001; 16.02.02.002	0.000783%		Not Available
Deafness neurosensory	17.04.07.001; 04.02.01.002	0.000313%		Not Available
Defaecation urgency	07.02.04.001	0.001159%		Not Available
Dehydration	14.05.05.001	-	-
Demyelination	17.16.02.001	0.000940%		Not Available
Dental caries	07.09.01.001	0.000313%
Depressed mood	19.15.02.001	-	-	Not Available
Dermal cyst	23.10.02.001; 16.26.02.001	0.000313%		Not Available
Dermatitis	23.03.04.002	0.001316%		Not Available
Dermatitis allergic	10.01.03.014; 23.03.04.003	0.000313%		Not Available
Dermatomyositis	10.04.04.027; 23.03.02.001; 15.05.01.002	0.000313%		Not Available
Diarrhoea	07.02.01.001	-	-
Diarrhoea haemorrhagic	24.07.02.004; 07.02.01.002	0.002882%		Not Available
Diffuse large B-cell lymphoma	16.28.02.001; 01.15.02.001	0.001723%		Not Available
Discomfort	08.01.08.003	-	-	Not Available
Disseminated intravascular coagulation	24.01.01.010; 01.01.02.002	0.000470%
Diverticulitis	11.01.07.003; 07.10.02.001	-	-	Not Available
Diverticulum	07.10.01.001	-	-	Not Available
Dizziness	02.11.04.006; 24.06.02.007; 17.02.05.003	-	-
Drug eruption	08.01.06.015; 23.03.05.001; 10.01.01.005	0.000470%		Not Available

The 4th Page First Pre 4 5 6 7 8 Next Last Total 25 Pages